Product-by-Process Claims Invalid when the Process Does Not Impart Structural or Functional Differences, PTAB Litigation Blog
Visit the Jones Day PTAB Litigation Blog.
The PTAB issued a final written decision in IPR2016-00006, holding claims 1–22 of U.S. Patent No. 8,497,393 ("the ’393 patent") unpatentable under 35 U.S.C. § 102(b) and 35 U.S.C. § 103(a). All of the claims are product-by-process claims to prostacyclin derivatives including treprostinil, the active ingredient in the pulmonary arterial hypertension drug Remodulin®.
Read the full article at ptablitigationblog.com.
